These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 3538403)

  • 21. Soluble unclottable complexes formed in the presence of fibrinogen degradation products (FDP) during the fibrinogen-fibrin conversion and their potential significance in pathology.
    Lipinski B; Wegrzynowicz Z; Budzynski AZ; Kopeć M; Latallo ZS; Kowalski E
    Thromb Diath Haemorrh; 1967 Feb; 17(1-2):65-77. PubMed ID: 5584961
    [No Abstract]   [Full Text] [Related]  

  • 22. [Relevance of fibrinogen/fibrin degradation products in the study of thrombosis].
    Páramo JA; Gaffney PJ
    Sangre (Barc); 1989 Dec; 34(6):497-501. PubMed ID: 2697948
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hemostatic changes related to anesthetic drugs and surgical intervention].
    Sparacia A; Mangione S; Sansone A
    Minerva Anestesiol; 1980 Jul; 46(7):791-814. PubMed ID: 7017462
    [No Abstract]   [Full Text] [Related]  

  • 24. [Somatostatin and the hemostatic system (author's transl)].
    Hnidec O
    Przegl Lek; 1980; 37(4):421-3. PubMed ID: 6105700
    [No Abstract]   [Full Text] [Related]  

  • 25. Fibrinogen degradation products do not affect the hypertensive action of dopamine.
    Buczko W; Wiśniewski K
    Acta Med Pol; 1986; 27(1-2):31-6. PubMed ID: 3565076
    [No Abstract]   [Full Text] [Related]  

  • 26. Biological properties of fibrinogen derivatives relevant to the function of cardiovascular system and immuno-inflammatory reaction.
    Kopec M
    New Istanbul Contrib Clin Sci; 1977 Sep; 12(1):43-9. PubMed ID: 565049
    [No Abstract]   [Full Text] [Related]  

  • 27. Aggregation of fibrinogen and its degradation products by basic proteins. An electron microscope study.
    Stewart GJ; Niewiarowski S
    Thromb Diath Haemorrh; 1971 Jun; 25(3):566-79. PubMed ID: 5105492
    [No Abstract]   [Full Text] [Related]  

  • 28. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
    Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
    Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of plasma coagulation by retransfusion of unwashed drainage blood after hip joint arthroplasty: a prospective study.
    Duchow J; Ames M; Hess T; Seyfert U
    J Arthroplasty; 2001 Oct; 16(7):844-9. PubMed ID: 11607899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Permeability enhancing and chemotactic activities of lower molecular weight degradation products of human fibrinogen.
    Sueishi K; Nanno S; Tanaka K
    Thromb Haemost; 1981 Feb; 45(1):90-4. PubMed ID: 7245130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mechanism of fibrinolysis (review of the literature)].
    Kovalenko AN
    Vrach Delo; 1983 Jan; (1):10-5. PubMed ID: 6223445
    [No Abstract]   [Full Text] [Related]  

  • 32. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fibrinogen and fibrin degradation products].
    Fujimaki M; Ikematsu S; Kato M
    Rinsho Byori; 1973 Jan; 21(1):31-6. PubMed ID: 4267650
    [No Abstract]   [Full Text] [Related]  

  • 34. [An analysis of a disorder in the fibrin-forming phase in virtually healthy middle-aged and elderly subjects by using the ancistron test].
    Platonova TN; Sushko OO; Lukinova NI; Solovĭov DA
    Fiziol Zh (1994); 1994; 40(3-4):63-70. PubMed ID: 7621957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catabolism of purified rat fibrin(ogen) plasmin degradation products in rats.
    Nieuwenhuizen W; Emeis JJ; Vermond A
    Thromb Haemost; 1982 Aug; 48(1):59-61. PubMed ID: 7135343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory assessment of circulating anticoagulants.
    Armitage JB; Hernandez JA; Kaplan HS
    Clin Lab Med; 1994 Dec; 14(4):795-812. PubMed ID: 7874872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Changes in platelet function in liver diseases].
    Castillo R; Casals FJ; Maragall S; Rodés J; Ordinas A
    Sangre (Barc); 1982; 27(4-B):672-9. PubMed ID: 7157140
    [No Abstract]   [Full Text] [Related]  

  • 38. Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
    Buczko W; De Blasi A
    Pol J Pharmacol Pharm; 1983; 35(1):45-7. PubMed ID: 6889186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions.
    Zwaginga JJ; Koomans HA; Sixma JJ; Rabelink TJ
    J Clin Invest; 1994 Jan; 93(1):204-11. PubMed ID: 8282789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased platelet and coagulatory activity in peripheral atherosclerosis flow mediated platelet function is a sensitive and specific disease indicator.
    Reininger CB; Graf J; Reininger AJ; Spannagl M; Steckmeier B; Schweiberer L
    Int Angiol; 1996 Dec; 15(4):335-43. PubMed ID: 9127775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.